MX356431B - Conjugados de anticuerpo farmaco. - Google Patents

Conjugados de anticuerpo farmaco.

Info

Publication number
MX356431B
MX356431B MX2015016417A MX2015016417A MX356431B MX 356431 B MX356431 B MX 356431B MX 2015016417 A MX2015016417 A MX 2015016417A MX 2015016417 A MX2015016417 A MX 2015016417A MX 356431 B MX356431 B MX 356431B
Authority
MX
Mexico
Prior art keywords
alkynyl
alkenyl
alkyl
coora
cora
Prior art date
Application number
MX2015016417A
Other languages
English (en)
Other versions
MX2015016417A (es
Inventor
Cuevas Marchante Cármen
Manuel Domínguez Correa Juan
Francesch Solloso Andrés
Garranzo García-Ibarrola María
José Munoz Alonso María
Sánchez Madrid Francisco
Manuel Zapata Hernández Juan
García Arroyo Alicia
Ángeles Ursa Pecharromán Maria
Original Assignee
Pharma Mar Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharma Mar Sa filed Critical Pharma Mar Sa
Publication of MX2015016417A publication Critical patent/MX2015016417A/es
Publication of MX356431B publication Critical patent/MX356431B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A61K47/6855—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell the tumour determinant being from breast cancer cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
    • C07D309/16—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D309/28—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D309/30—Oxygen atoms, e.g. delta-lactones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
    • C07D309/32—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Pyrane Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La presente invención se refiere a conjugados de fármaco de fórmula [D-(X)b-(AA)W-(L)-]n-Ab en la que: D es un resto de fármaco que tiene la siguiente fórmula (I) o una sal, éster, solvato, tautómero o estereoisómero aceptable desde el punto de vista farmacéutico, en la que: A se selecciona de (II) y (III) R1, R2 y R3 es H, ORa, OCORa, OCOORa, alquilo, alquenilo, alquinilo, etc; R3' es, CORa, COORa, CONRaRb, etc; cada uno de R4 a R10 y R12 es alquilo, alquenilo, o alquinilo; R11 es H, CORa, COORa, alquilo, alquenilo o alquinilo, o R11 y R12+N+C átomos a los cuales se unen pueden formar un grupo heterocíclico; cada uno de R13 y R14 es H, CORa, COORa, alquilo, alquenilo o alquinilo; cada uno de Ra y Rb es H, alquilo, alquenilo, alquinilo, etc.; cada línea punteada representa un enlace adicional opcional; X es un grupo extensor; AA es una unidad de aminoácido; L es un grupo conector; w es 0 a 12; b es 0 o 1; Ab es un resto que comprende al menos un sitio de unión al antígeno, y n es la relación del grupo [D-(X)b-(AA)W-(L)-] al resto que comprende al menos un sitio de unión al antígeno y está en el intervalo de 1 a 20, son útiles en el tratamiento de cáncer. (ver Fórmula).
MX2015016417A 2013-05-31 2014-06-02 Conjugados de anticuerpo farmaco. MX356431B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB1309807.4A GB201309807D0 (en) 2013-05-31 2013-05-31 Antibody drug conjugates
PCT/EP2014/061392 WO2014191578A1 (en) 2013-05-31 2014-06-02 Antibody drug conjugates

Publications (2)

Publication Number Publication Date
MX2015016417A MX2015016417A (es) 2016-07-05
MX356431B true MX356431B (es) 2018-05-29

Family

ID=48805601

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2015016417A MX356431B (es) 2013-05-31 2014-06-02 Conjugados de anticuerpo farmaco.

Country Status (29)

Country Link
US (2) US11224663B2 (es)
EP (1) EP3003386B1 (es)
JP (1) JP6412114B2 (es)
KR (2) KR102448393B1 (es)
CN (1) CN105451775B (es)
AR (2) AR096461A1 (es)
AU (1) AU2014273052B2 (es)
BR (1) BR112015029816B1 (es)
CA (1) CA2914041C (es)
CL (1) CL2015003481A1 (es)
CY (1) CY1122662T1 (es)
DK (1) DK3003386T3 (es)
ES (1) ES2778045T3 (es)
GB (1) GB201309807D0 (es)
HR (1) HRP20200032T1 (es)
IL (1) IL242571B (es)
LT (1) LT3003386T (es)
MX (1) MX356431B (es)
MY (1) MY176579A (es)
NZ (1) NZ715646A (es)
PL (1) PL3003386T3 (es)
PT (1) PT3003386T (es)
RS (1) RS59855B1 (es)
RU (1) RU2669812C2 (es)
SG (1) SG11201509563UA (es)
SI (1) SI3003386T1 (es)
UA (1) UA119327C2 (es)
WO (1) WO2014191578A1 (es)
ZA (1) ZA201508487B (es)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016089610A1 (en) * 2014-12-06 2016-06-09 H. Lee Moffitt Cancer Center And Research Institute, Inc. Bispecific antibody for cancer immunotherapy
CN116726183A (zh) * 2015-08-03 2023-09-12 Enb治疗公司 用于治疗与etbr激活相关的癌症的组合物和方法
PE20231050A1 (es) 2016-03-02 2023-07-11 Eisai Randd Man Co Ltd Conjugados de anticuerpo y farmaco basados en eribulina y metodos para su uso
EP3381474A1 (en) * 2017-03-27 2018-10-03 Alfasigma S.p.A. Histone deacetylase inhibitors-based antibody drug conjugates (adcs) and use in therapy
JOP20190254A1 (ar) 2017-04-27 2019-10-27 Pharma Mar Sa مركبات مضادة للأورام
AU2018375412A1 (en) * 2017-11-30 2020-05-28 Seagen Inc. Process for the preparation of drug linker compounds
PE20201464A1 (es) * 2017-12-01 2020-12-17 Abbvie Inc Conjugados anticuerpo anti-cd40-farmaco
SG11202006510XA (en) 2018-01-08 2020-08-28 Regeneron Pharma Steroids and antibody-conjugates thereof
MA53933A (fr) * 2018-10-21 2021-08-25 Slsg Ltd Llc Poly-immunothérapie pour le traitement du cancer du sein triple-négatif
CN118027137A (zh) 2018-12-21 2024-05-14 里珍纳龙药品有限公司 微管溶素及蛋白质-微管溶素偶联物
EP3964236A4 (en) * 2019-05-02 2023-05-31 LegoChem Biosciences, Inc. LIGAND-DRUG CONJUGATE COMPRISING A LINKER HAVING A TRIS STRUCTURE
US20220226496A1 (en) * 2019-05-02 2022-07-21 Legochem Biosciences, Inc. Ligand-drug conjugate including linker having tris structure
WO2020229982A1 (en) * 2019-05-10 2020-11-19 Takeda Pharmaceutical Company Limited Antibody drug conjugates
WO2020233174A1 (zh) * 2019-05-20 2020-11-26 烟台迈百瑞国际生物医药有限公司 一种抗体药物偶联物中间体的一锅法制备工艺
CN114262377B (zh) * 2021-10-28 2024-03-22 新疆优迈生物技术有限公司 一种阻断cd70与其配体cd27结合的抗人cd70纳米抗体的制备方法及其编码序列

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7659241B2 (en) 2002-07-31 2010-02-09 Seattle Genetics, Inc. Drug conjugates and their use for treating cancer, an autoimmune disease or an infectious disease
CA2516455C (en) * 2003-02-20 2012-05-01 Seattle Genetics, Inc. Anti-cd70 antibody-drug conjugates and their use for the treatment of cancer and immune disorders
US8088387B2 (en) 2003-10-10 2012-01-03 Immunogen Inc. Method of targeting specific cell populations using cell-binding agent maytansinoid conjugates linked via a non-cleavable linker, said conjugates, and methods of making said conjugates
WO2006060533A2 (en) 2004-12-01 2006-06-08 Genentech, Inc. Conjugates of 1, 8-bis-naphthalimides with an antibody
EP1864682A1 (en) * 2006-06-09 2007-12-12 Sanofi-Aventis Leptomycin derivatives
CN102336730A (zh) * 2006-06-16 2012-02-01 马尔药品公司 抗肿瘤二羟基吡喃-2-酮化合物
RS52343B (en) * 2007-12-20 2012-12-31 Pharma Mar S.A. ANTITUMOR UNITS
NZ588526A (en) 2008-05-23 2012-08-31 Wyeth Llc Triazine compounds as pi3 kinase and mtor inhibitors
WO2010009124A2 (en) 2008-07-15 2010-01-21 Genentech, Inc. Anthracycline derivative conjugates, process for their preparation and their use as antitumor compounds
WO2010149688A2 (en) * 2009-06-24 2010-12-29 Pharma Mar, S.A. Antitumoral compounds

Also Published As

Publication number Publication date
HRP20200032T1 (hr) 2020-03-20
CA2914041A1 (en) 2014-12-04
RU2015156499A3 (es) 2018-03-27
RU2015156499A (ru) 2017-06-30
AU2014273052A1 (en) 2016-01-28
BR112015029816A2 (pt) 2017-07-25
US11224663B2 (en) 2022-01-18
PT3003386T (pt) 2020-01-21
DK3003386T3 (da) 2020-01-27
US20160129128A1 (en) 2016-05-12
PL3003386T3 (pl) 2020-04-30
ES2778045T3 (es) 2020-08-07
BR112015029816B1 (pt) 2022-10-04
CL2015003481A1 (es) 2016-08-19
AR123672A2 (es) 2023-01-04
WO2014191578A1 (en) 2014-12-04
IL242571B (en) 2019-10-31
RS59855B1 (sr) 2020-02-28
KR20160030132A (ko) 2016-03-16
MX2015016417A (es) 2016-07-05
KR20210156848A (ko) 2021-12-27
GB201309807D0 (en) 2013-07-17
KR102340681B1 (ko) 2021-12-20
CY1122662T1 (el) 2021-03-12
CN105451775B (zh) 2019-09-06
KR102448393B1 (ko) 2022-09-28
AR096461A1 (es) 2015-12-30
US20220168436A1 (en) 2022-06-02
NZ715646A (en) 2019-05-31
ZA201508487B (en) 2017-11-29
AU2014273052B2 (en) 2018-03-08
LT3003386T (lt) 2020-01-27
EP3003386A1 (en) 2016-04-13
EP3003386B1 (en) 2019-10-16
CN105451775A (zh) 2016-03-30
SG11201509563UA (en) 2015-12-30
JP6412114B2 (ja) 2018-10-24
SI3003386T1 (sl) 2020-03-31
JP2016526042A (ja) 2016-09-01
RU2669812C2 (ru) 2018-10-16
CA2914041C (en) 2021-12-07
MY176579A (en) 2020-08-17
UA119327C2 (uk) 2019-06-10

Similar Documents

Publication Publication Date Title
MX356431B (es) Conjugados de anticuerpo farmaco.
MX2010006799A (es) Benzofuropirimidinonas como inhibidores de la proteina cinasa.
NZ725131A (en) Tubulysin derivatives
RU2016134258A (ru) Конъюгат лекарственного средства с направляющей молекулой и двумя различными лекарственными средствами
CY1118721T1 (el) Παραγωγα 2,3 διϋδρο-1η-ινδεν-1-υλ-2,7-διαζασπειρο[3.6]εννεανιου και η χρηση αυτων ως ανταγωνιστες ή αντιστροφοι αγωνιστες του υποδοχεα γκρελινης
HRP20090077A2 (en) Modulators of pharmacokinetic properties of therapeutics
NZ705394A (en) Antibody-drug conjugate
NZ604718A (en) Human antibody drug conjugates against tissue factor
WO2020056198A3 (en) Substituted benzazepine compounds, conjugates, and uses thereof
CY1114908T1 (el) Παραγωγα κινολινης ως αντιβακτηριακοι παραγοντες
EA201491607A1 (ru) Модуляторы толлподобных рецепторов
EA200870448A1 (ru) Тризамещенные 1,2,4-триазолы
IN2014CN04961A (es)
JO2744B1 (en) Cytotoxic agents, including new tomaymycin derivatives and their therapeutic use
JP2016506962A5 (es)
EA201170922A1 (ru) Производные сульфонамида
WO2015118030A3 (en) Antibody-drug conjugates and immunotoxins
EA201001724A1 (ru) Производные изоксазола и их применение в качестве потенциирующих средств для метаботропных глутаматных рецепторов
MX2009011573A (es) Metodos de reduccion de nefrotoxicidad en sujetos administrados con nucleosido.
SA521421855B1 (ar) مترافقات عقار-جسم مضاد
UA95959C2 (en) Leptomycin derivatives
EA201071094A1 (ru) Тризамещенные 1,2,4-триазолы в качестве модуляторов никотиновых ацетилхолиновых рецепторов
BRPI0518993A2 (pt) composto ou um sal, solvato ou Éster farmaceuticamente aceitÁvel do mesmo, composiÇço farmacÊutica, e, uso de um composto
EA200870421A1 (ru) Димеры производных артемизинина, их получение и их применение в терапии
MY173890A (en) Crystalline naloxol-peg conjugate

Legal Events

Date Code Title Description
FG Grant or registration